Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 8/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | CA9 | Q16790 | 1/20 | 0.70 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713787 | 0.86 | PANK3 (0.76) | PANK3CA12CA1CA2CA9 | |
| SCHEMBL6430270 | 0.85 | TRPV1 (0.79) | PANK3TRPV1 | |
| SCHEMBL6430141 | 0.85 | TRPA1 (0.74) | PANK3TRPV1 | |
| SCHEMBL14423741 | 0.84 | PANK3 (0.72) | PANK3TRPV1 | |
| SCHEMBL14423742 | 0.84 | PANK3 (0.72) | PANK3TRPV1 | |
| SCHEMBL6430919 | 0.81 | TRPV1 (0.77) | PANK3CA12CA1CA2CA9 | |
| SCHEMBL13931351 | 0.78 | TRPV1 (0.71) | PANK3CA12CA1CA2CA9 | |
| SCHEMBL21424057 | 0.78 | PANK3 (1.00) | PANK3CA12CA1CA2CA9 | |
| SCHEMBL21406387 | 0.78 | PANK3 (1.00) | PANK3TRPV1 | |
| SCHEMBL19748824 | 0.77 | PANK3 (1.00) | PANK3TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176443-A1 | Capsaicin receptor ligands | NEUROGEN CORPORATION | 2004-09-09 | — | — | US | claimed |
| EP-1301484-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020132853-A1 | Capsaicin receptor ligands | NEUROGEN CORPORATION | 2002-09-19 | — | — | US | claimed |
| WO-2002008221-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-31 | — | — | WO | claimed |
| US-12552765-B2 | Small molecule modulators of pantothenate kinases | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2026-02-17 | — | — | US | disclosed |
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547709-B2 | Methods of treating disorders associated with castor | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022133034-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-08-12 | — | — | US | disclosed |
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-08-12 | — | — | US | disclosed |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2019-10-03 | — | — | US | disclosed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | PANK3 1573/4885CA12 902/4885CA1 1205/4885 |
| US-11547709-B2 | Methods of treating disorders associated with castor | HMGCR, GCDH, CYP11A1 | PANK3 1573/4885CA12 902/4885CA1 1205/4885 |
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | PANK3 3/4885CA12 4654/4885CA1 4709/4885 |
| US-20040176443-A1 | Capsaicin receptor ligands | TRPV1, TRPV5, TRPV2 | PANK3 3212/4885CA12 2322/4885CA1 2157/4885 |
| US-12552765-B2 | Small molecule modulators of pantothenate kinases | PANK3, PANK1, PANK2 | PANK3 1/4885CA12 3303/4885CA1 1990/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | PANK3 2016/4885CA12 3808/4885CA1 1643/4885 |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | PANK3 1573/4885CA12 902/4885CA1 1205/4885 |
| US-20020132853-A1 | Capsaicin receptor ligands | TRPV1, TRPV5, TRPV2 | PANK3 3212/4885CA12 2322/4885CA1 2157/4885 |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | PANK3 3/4885CA12 4654/4885CA1 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.